Previous studies have reported that CBP/p300 epigenetically regulates the expression of glycolysis-related metabolic enzymes through the modulation of histone acetylation in HCC and highlights the value of targeting the histone acetyltransferase activity of CBP/p300 for HCC therapy [43]. The gene discussed is EP300; the disease is hepatocellular carcinoma.